{
  "nctId": "NCT02480803",
  "briefTitle": "INfusion VErsus STimulation in Parkinson's Disease",
  "officialTitle": "Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation",
  "protocolDocument": {
    "nctId": "NCT02480803",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2019-10-07",
    "uploadDate": "2022-03-09T07:19",
    "size": 431173,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02480803/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 51,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2014-12-19",
    "completionDate": "2024-01-26",
    "primaryCompletionDate": "2021-12-07",
    "firstSubmitDate": "2015-05-04",
    "firstPostDate": "2015-06-25"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry;\n* Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia;\n* A life expectancy of at least two years.\n\nExclusion Criteria:\n\n* Age below 18 years\n* Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);\n* Previous CLI (through a PEG-tube or Nasal Jejuna\\| tube);\n* Hoehn and Yahr stage 5 at the best moment during the day;\n* Other severely disabling disease;\n* Dementia or signs of severe cognitive impairment\n* Psychosis;\n* Current depression;\n* Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;\n* Contraindications for PEG surgery such as interposed organs, ascites and oesophagogastric varices, or for Duodopa;\n* Pregnancy, breastfeeding, and women of child bearing age not using a reliable method of contraception;\n* No informed consent;\n* Legally incompetent adults;",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Cost effectiveness in costs per changed unit on PDQ-39",
        "description": "The costs per changed unit on the PDQ-39.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Cost-utility in costs per changed Quality Adjusted Life Year (QALY, years)",
        "description": "The costs per QALY. The EuroQol 5D-3L (EQ-5D; 5 questions, each score 1-3, providing a health state, to be translated with provided Valuation set) will be applied as the utility measure.",
        "timeFrame": "12 months"
      }
    ],
    "secondary": [
      {
        "measure": "Quality of life (on PDQ-39)",
        "description": "Changes from Baseline on Parkinson's Disease Questionnaire-39 (PDQ-39; score 0-100, higher score is lower quality of life)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Quality of life (on EQ-5D)",
        "description": "Change from Baseline on EuroQol 5D-3L (EQ-5D; 5 questions, each score 1-3, providing a health state, to be translated with provided Valuation set)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Motor symptoms",
        "description": "Score changes from Baseline in off and on state on Movement Disorder Society's Unified Parkinson Disease Rating Scale (MDS-UPDRS part 3; 0-132, high score is more motor symptoms)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Motor symptoms: time in off and on-state",
        "description": "Change from Baseline in time in off-state, on-state without dyskinesias, on-state without troublesome dyskinesias and on-state with troublesome dyskinesias measured with motor symptom diary",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Motor experiences of daily living",
        "description": "Changes from Baseline on MDS-UPDRS part 2 (Movement Disorder Society's Unified Parkinson Disease Rating Scale (MDS-UPDRS part 2; score 0-52, high score is more worse health)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Dyskinesia",
        "description": "Change from Baseline on clinical Dyskinesia Rating Scale (CDRS; score 0-28, high score is more dyskinesia)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "PD-medication (levodopa-equivalent dose)",
        "description": "Change from Baseline expressed in levodopa-equivalent dose",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Functional health status",
        "description": "Change from Baseline on Amsterdam Linear Disability Score (ALDS, 29 items; 0-100, high score is high level of functional status)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Non-motor symptoms (Non Motor Symptom Checklist)",
        "description": "Changes from Baseline on Non Motor Symptom Checklist",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Non-motor symptoms (Rotterdam Symptom Checklist",
        "description": "Change from Baseline on Rotterdam Symptom Checklist",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Non-motor symptoms (SCOPA-AUT)",
        "description": "Change from Baseline on SCOPA-AUT (SCales for Outcomes in PArkinson's Autonomic symptoms; score 0-92, higher score is more symptoms)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Disability",
        "description": "Change from Baseline in Hoehn and Yahr stage (H\\&Y stage; 1-5: a higher score is more disease progression)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Cognitive functioning",
        "description": "Change from Baseline on Parkinson's Disease Cognition Rating Scale (PD-CRS; 0-134, higher score is a result of better cognitive performance)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Cognitive functioning Mattis",
        "description": "Change from Baseline in Mattis Dementia Rating score (score 0-144, higher score is better cognitive function)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning BNT",
        "description": "Change from Baseline in Boston Naming Test (range 0-30, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Letter Fluency",
        "description": "Change from Baseline in Letter Fluency (score 0-100, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning WAIS IV",
        "description": "Change from Baseline in WAIS IV (Wechsler Adult Intelligence Scale IV - subsection similarities; score 0-36, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Reading",
        "description": "Change from Baseline in Dutch Reading Test (0-100, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Word Test",
        "description": "Change from Baseline in 15 word test (0-75, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Memory",
        "description": "Change from Baseline in Rivermead Behavioral memory test (subsection stores; score 0-42, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Trail making",
        "description": "Change from Baseline in Trail making test (score 10-500, higher score is longer time, i.e. worse score)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Color Word",
        "description": "Change from Baseline in Stroop Color Word Test (score 10-1000, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Line Orientation",
        "description": "Change from Baseline in Judgement of line orientation (score 0-30, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Neuropsychologic functioning Clock",
        "description": "Change from Baseline in Clock construction (score 0-14, higher is better)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Psychiatric disease",
        "description": "Change from Baseline in Mini International Neuropsychiatric Interview",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Apathy",
        "description": "Change from Baseline in Starkstein's Apathy Scale (SAS; score 0-42, high score is more signs of apathy)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Compulsive Disorders",
        "description": "Change in presence of Compulsive Disorder from Baseline assessed with Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire (QUIP, utilizing established thresholds)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Anxiety",
        "description": "Changes from Baseline on Hamilton Anxiety Scale (HAM-A; 0-56, high score is worse outcome)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Depression",
        "description": "Change from Baseline on Hamilton Depression Rating Scale (HDRS; 0-68, higher score is worse outcome)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Suicidality",
        "description": "Changes from Baseline on Columbia Suicide Severity Rating Scale (range 0-25, higher score is worse outcome)",
        "timeFrame": "12 and 36 months"
      },
      {
        "measure": "Adverse effects",
        "description": "Number of participants with adverse effects and description of these",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Complications and description of complications",
        "description": "Number of participants with complications and description of these",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Stopping allocated treatment",
        "description": "Number of participants who stopped treatment",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Treatment failure",
        "description": "Number of participants with treatment failure",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Treatment cross-over",
        "description": "Number of participants with treatment cross-over",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Patient satisfaction",
        "description": "Descriptive questionnaire, no scale applied, descriptive statistics",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Patients attitude to treatment",
        "description": "Change from Baseline on Patient Reported Outcome Scale (range 0-128, high score is worse outcome)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Medical costs",
        "description": "Calculation of the total costs in euro by means of iMCQ (iMTA Medical Consumption Questionnaire)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Non-medical care costs",
        "description": "Calculation of the total costs in euro by means of iPCQ (iMTA Productivity Cost Questionnaire)",
        "timeFrame": "12, 24 and 36 months"
      },
      {
        "measure": "Caregiver burden",
        "description": "Descriptive questionnaire, no scale applied, descriptive statistics",
        "timeFrame": "12, 24 and 36 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 40,
      "otherCount": 0,
      "totalCount": 42
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:46.390Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}